Real-world data on immunotherapy combined with chemotherapy in elderly patients with extensive-stage small cell lung cancer.

ABSTRACT:

Background

Immunotherapy combined with chemotherapy has shown good results in the treatment of extensive-stage small cell lung cancer (ES-SCLC), but there are fewer clinical studies on elderly ES-SCLC patients. This study was aimed to evaluate the efficacy and safety of immunotherapy in combination with chemotherapy in elderly patients with ES-SCLC.

Methods

Elderly patients with ES-SCLC who were 70 years of age or older and were diagnosed at Shandong Cancer Hospital from May 20, 2020, to February 24, 2023, were included in this study. Overall survival (OS) and progression-free survival (PFS) were calculated via the Kaplan‒Meier method and compared via the log-rank test. In addition, the Cox regression model was used to analyze prognostic factors.

Results

A total of 13

SUBMITTER: Zhao K 

PROVIDER: S-EPMC11907774 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature